For General Information, page-2845

Thanks Arjay, I found this to be a powerful paragraph re BIO

With Imugene investor sentiment at all time lows in spite of the company's brilliant science, the chickens must surely be coming home to roost for a management team whose blind faith in their science and perceived disdain for shareholder opinion has left them without a clear and distinct commercial pathway for investors and the market to hang their hat on. At present the lack of upfront or prospective milestone payments for their products, the absence of a corporate partner, such as Roche (see above), has left many wondering what is the road to market for Imugene, and when it is going to occur. Spreading oneself to thin could be the outcome of a strategy wherein Imugene continues to develop multiple oncology platforms across multiple cancer indications. Let us hope this indeed is not the situation, as many more shareholders are now on the register than before the capital raises of recent years began. I guess by building a mini Genentec the long term value of Imugene could indeed be far greater than the sum of their remaining parts, were my above mentioned licensing and partnership scenario to have occurred. However I for one would prefer to see Imugene in a position to develop their best technology, Vaxinia, in order for it to reach its ultimate potential, rather than having to sell the company as a whole prior to that occurring, due to a lack of funds and ongoing revenue. Or to put it bluntly the lack of a commercial partner such as Roche.